# IXICO reports strong H1 revenue growth as Alzheimer’s trial demand accelerates 19 May 26 news # IXICO reports strong H1 revenue growth as Alzheimer’s trial demand accelerates [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/ixico-reports-strong-h1-revenue-growth-as-alzheimers-trial-demand-accelerates/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/ixico-reports-strong-h1-revenue-growth-as-alzheimers-trial-demand-accelerates/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/ixico-reports-strong-h1-revenue-growth-as-alzheimers-trial-demand-accelerates/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/ixico-reports-strong-h1-revenue-growth-as-alzheimers-trial-demand-accelerates/) [ Play Video ](https://youtube.com/watch?v=oPxj8zclPrQ "Play Video") IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Stephen Gunnion to discuss the company’s interim results, growing Alzheimer’s trial demand and expanding TechBio strategy. Goorden said IXICO delivered 23% revenue growth and a 38% increase in its order book, with strong visibility into FY2026 revenues. Growth has been driven by new contracts, study extensions and increasing momentum in later-stage Alzheimer’s programmes. He also highlighted expanding opportunities in neurodegenerative diseases, including Parkinson’s, and growing partnerships in diagnostics and blood-based biomarkers for Alzheimer’s research. The interview covered IXICO’s recent £10 million fundraising and plans to scale its IXI technology platform, including the launch of version 10 with enhanced automation, processing speed and data capacity. For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications for future content. [ Back to News ](/news-and-resources/news/) ### Recents ![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 2 Nov 26 news [IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/) [IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/) [IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) ### Library [November 2026](/news-and-resources/news/archive/2026/11/) [October 2026](/news-and-resources/news/archive/2026/10/) [September 2026](/news-and-resources/news/archive/2026/09/) [July 2026](/news-and-resources/news/archive/2026/07/) [June 2026](/news-and-resources/news/archive/2026/06/) [May 2026](/news-and-resources/news/archive/2026/05/) [April 2026](/news-and-resources/news/archive/2026/04/) [March 2026](/news-and-resources/news/archive/2026/03/) [February 2026](/news-and-resources/news/archive/2026/02/) [January 2026](/news-and-resources/news/archive/2026/01/) [2025](/news-and-resources/news/archive/2025/) [2024](/news-and-resources/news/archive/2024/) [2023](/news-and-resources/news/archive/2023/) [2022](/news-and-resources/news/archive/2022/) [2021](/news-and-resources/news/archive/2021/) [2020](/news-and-resources/news/archive/2020/) [2019](/news-and-resources/news/archive/2019/)